News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BioNTech reported Q2 2026 earnings, with total revenue down to EUR 106 million due to lower COVID-19 vaccine demand and the absence of a prior-year payment from Pfizer. The company revised its full-year revenue guidance to EUR 1.6 billion to EUR 1.9 billion, reflecting …
BioNTech SE (BNTX) is a biotechnology company facing financial challenges with negative profitability metrics and significant revenue decline, despite its strong pipeline in oncology and infectious diseases. Analysts, however, see a potential upside of 28.66% with an average target price of $120.52, supported by …
Bank of New York Mellon Corp significantly reduced its stake in BioNTech SE by 64.6% in the first quarter, selling over 73,000 shares but still retaining shares worth approximately $3.6 million. Despite a reported quarterly loss, BioNTech outperformed EPS estimates, although revenue missed expectations …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition …
BioNTech SE's latest quarterly report has led to a darkening of analyst consensus forecasts, with analysts cutting revenue predictions by 19% and earnings per share forecasts by 22%. Despite these downward revisions, the consensus price target remains stable at US$139, suggesting that the market …
BioNTech SE recently reported disappointing quarterly results, with revenues missing forecasts and losses exceeding expectations. Consequently, analysts have significantly cut next year's revenue estimates and increased loss per share forecasts, though the average price target remained unchanged. The company's revenue is expected to continue …
This article provides a revenue breakdown for BioNTech SE Sponsored ADR (BSESOF:22UA). It highlights that the company generated 2.87 billion EUR last year, with Immunotherapy Technologies being the top-performing segment, contributing 2.76 billion EUR. The United States was the largest regional contributor, accounting for …
BioNTech SE (NASDAQ:BNTX) recently received significant downgrades from analysts, with cuts to both revenue and earnings per share forecasts for 2026. Analysts now predict a 30% decline in sales to €1.9 billion and increased losses of €5.45 per share, indicating a negative shift in …
BioNTech SE (BNTX) reported its Q2 earnings, missing analyst estimates for both EPS and revenue. The company posted a Q2 EPS of (EUR2.22), which was EUR0.18 worse than the estimated (EUR2.04), and revenue came in at EUR105.6 million, significantly below the consensus estimate of …
BioNTech SE's average 12-month price target has been adjusted to $121.53, down from $122.4, according to 19 analysts, with a potential upside of approximately 32% from its Aug. 3 closing price. The consensus rating from 21 analysts remains a "Buy," with 15 Buys and …
Earnings Call Insights: BioNTech (BNTX) Q2 2026 MANAGEMENT VIEW * BioNTech framed its leadership transition as tied to commercialization scale, with (Chairman Helmut Jeggle) saying, "Guido Oelkers will take office as CEO as of February 1 at the latest" and highlighting that, at Sobi, …
BioNTech, a German biotech company founded in 2008, is a leader in personalized mRNA cancer treatments. Having capitalized on its COVID-19 vaccine success, the company has diversified its pipeline through acquisitions, focusing on biologic drug candidates in oncology. These new treatments are expected to …
BioNTech has significantly lowered its 2026 full-year sales outlook due to weaker-than-expected demand for its COVID-19 vaccine, resulting in a more than halved second-quarter revenue and a doubled net loss. The company now projects 2026 revenue between €1.6 billion and €1.9 billion, down from …
Key Points Interested in BioNTech SE Sponsored ADR? Here are five stocks we like better. BioNTech's Q2 revenue fell to €106 million from €261 million a year earlier due to weaker U.S. COVID-19 vaccine demand. The company lowered 2026 revenue guidance to €1.6 billion–€1.9 …
BioNTech SE announced its financial results for the second quarter and six months ended June 30, 2026, reporting a significant decrease in sales and an increase in net loss compared to the previous year. For the second quarter, sales were EUR 105.6 million and …
BioNTech SE (BNTX) reported its Q2 2026 earnings, missing analyst estimates for both EPS and revenue. The company's EPS was -$2.22 against an estimated -$2.08, and revenue was $106M compared to an estimated $156M. Management also lowered full-year 2026 guidance due to Germany drawing …
BioNTech SE Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple …
BioNTech reported a significant Q2 2026 loss of €820.8 million and sharply lower COVID-19 vaccine revenue, leading the company to reduce its full-year 2026 revenue guidance to €1.6–1.9 billion from €2.0–2.3 billion. Despite the financial setbacks, BioNTech is advancing its oncology pipeline with 14 …
BioNTech announced that Guido Oelkers, the current CEO of Sobi, will take over as its chief executive from February 1, 2027, at the latest. Oelkers will succeed Ugur Sahin, who along with co-founder Oezlem Tuereci, is set to leave the company by the end …
BioNTech is set to report its second-quarter results with analysts expecting widening losses due to a significant decline in COVID-19 vaccine revenue. Despite the short-term financial headwinds, the company is pivoting towards oncology with promising clinical trial developments in mRNA cancer vaccines. Investors will …
(RTTNews) - BioNTech SE (BNTX) announced on Monday that its Supervisory Board has appointed Guido Oelkers to the Management Board as Chief Executive Officer (CEO), effective February 1, 2027, succeeding co-founder and CEO Ugur Sahin. Sahin is a physician and immunologist with experience in …
BioNTech SE has announced the appointment of Guido Oelkers, Ph.D., as its new Chief Executive Officer, succeeding co-founder Prof. Ugur Sahin, M.D. Oelkers, who previously quadrupled revenues at Swedish Orphan Biovitrum AB, is expected to take office by February 1, 2027, and aims to …
BioNTech SE has appointed Guido Oelkers, Ph.D., to its Management Board as Chief Executive Officer, effective by February 1, 2027. Oelkers, who previously served as CEO of Swedish Orphan Biovitrum AB, brings over 30 years of experience in the biotechnology and pharmaceutical industries. This …
BioNTech SE has appointed Guido Oelkers, Ph.D., as its new Chief Executive Officer, effective by February 1, 2027, succeeding Prof. Ugur Sahin, M.D. Oelkers brings over 30 years of experience in the biotechnology and pharmaceutical industries and a strong track record of increasing revenue …
This article provides financial data for BioNTech SE (NASDAQ: BNTX), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot from a financial data platform, showing the company's ticker, market, and a period value related to this metric, but …
(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Commission (EC) has granted marketing authorisation for the COVID-19 vaccine formulation targeting the XFG variant, for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and …
This article provides a comprehensive stock analysis of BioNTech SE (BNTX), highlighting its healthy fundamentals and high growth potential. The stock is considered fairly valued and has high institutional ownership, with analysts rating it as a "Buy" with a price target of $127.65. Despite …
Pfizer Inc. and BioNTech SE have received European Commission authorization for their 2026-2027 COVID-19 vaccine, which targets the XFG variant, for individuals aged 6 months and older. This authorization, based on an EMA recommendation, is valid across the EU, Iceland, Liechtenstein, and Norway. The …
This article provides a valuation analysis of Biontech SE (BNTX) as of July 28, 2026. The company's current valuation score is 9.11, ranking 55th in the Biotechnology & Medical Research industry. It notes a P/E ratio of -21.06, while P/B, P/S, and P/CF data …
Search by ticker symbol or company name and select a result to open its chart.